Previous Article | Next Article 
Infection and Immunity, June 2000, p. 3286-3289, Vol. 68, No. 6
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Overexpression of Protective Antigen as a Novel
Approach To Enhance Vaccine Efficacy of Brucella abortus
Strain RB51
Ramesh
Vemulapalli,*
Yongqun
He,
Silvio
Cravero,
Nammalwar
Sriranganathan,
Stephen M.
Boyle, and
Gerhardt G.
Schurig
Department of Biomedical Sciences and
Pathobiology, Center for Molecular Medicine and Infectious Diseases,
Virginia-Maryland Regional College of Veterinary Medicine, Virginia
Polytechnic Institute and State University, Blacksburg, Virginia 24061
Received 10 December 1999/Returned for modification 10 February
2000/Accepted 20 March 2000
 |
ABSTRACT |
Brucella abortus strain RB51 is an attenuated rough
strain that is currently being used as the official live vaccine for
bovine brucellosis in the United States and several other countries. We
reasoned that overexpression of a protective antigen(s) of B. abortus in strain RB51 should enhance its vaccine efficacy. To
test this hypothesis, we overexpressed Cu/Zn superoxide dismutase (SOD)
protein of B. abortus in strain RB51. This was accomplished by transforming strain RB51 with a broad-host-range plasmid, pBBR1MCS, containing the sodC gene along with its promoter. Strain
RB51 overexpressing SOD (RB51SOD) was tested in BALB/c mice for its ability to protect against challenge infection with virulent strain 2308. Mice vaccinated with RB51SOD, but not RB51, developed antibodies and cell-mediated immune responses to Cu/Zn SOD. Strain RB51SOD vaccinated mice developed significantly (P < 0.05)
more resistance to challenge than those vaccinated with strain RB51
alone. The presence of the plasmid alone in strain RB51 did not alter
its vaccine efficacy. Also, overexpression of SOD did not alter the attenuation characteristic of strain RB51.
 |
INTRODUCTION |
Intracellular bacteria are
responsible for several important infectious diseases of animals and
humans. Cell-mediated immune (CMI) responses play a critical role in
resistance against intracellular bacterial infections (7).
Live bacterial vaccines are considered essential for effectively
inducing the appropriate protective CMI responses. Usually, attenuated
strains of bacteria are used as live vaccines for intracellular
bacterial infections. However, in many cases, even these live vaccines
cannot provide high levels of protection. We hypothesized that
overexpression of a bacterial protective antigen(s) in its vaccine
strain would result in enhancement of the vaccine's efficacy. Our
studies with Brucella abortus vaccine strain RB51 validate
this hypothesis.
Members of the genus Brucella are small gram-negative,
facultatively intracellular bacteria of zoonotic importance
(1). These bacteria are causative agents of brucellosis, a
chronic disease of animals and humans. In animals, this disease often results in infertility and abortions leading to severe economic losses
to livestock producers (5). Humans acquire the infection by
coming in contact with the infected materials or by consuming contaminated meat or dairy products. B. abortus is primarily
responsible for brucellosis in cattle. B. abortus strain
RB51, an attenuated rough mutant developed in our laboratory
(20), is presently being used in several countries as a live
vaccine for the control and eradication of brucellosis in cattle.
Similar to most of the intracellular bacterial infections, CMI appears
to play a major role in acquired resistance to brucellosis, although
antibodies to surface antigens, especially to the O antigen, can confer
certain level of protection against a challenge infection in some host species, such as the mouse (2, 5). Studies of mice indicate that protection afforded by strain RB51 vaccination is primarily through induction of specific CMI (6).
Although several immunoreactive antigens of B. abortus have
been characterized, little is known about the specific proteins necessary for inducing the protective immune responses. Peptides comprising certain epitopes, but not the complete recombinant protein,
of Cu/Zn superoxide dismutase (SOD) of B. abortus have been
shown to induce partial protection against challenge infection with
virulent strain 2308 (25). Further, studies involving
vaccination of mice with live Escherichia coli expressing
the Brucella Cu/Zn SOD indicated a protective role for this
antigen against Brucella infections (13). In this
paper, we demonstrate that overexpression of B. abortus
Cu/Zn SOD protein in vaccine strain RB51 significantly increases its
protective capabilities in the murine model of brucellosis without
altering the attenuation characteristics of the vaccine.
 |
MATERIALS AND METHODS |
Bacteria.
B. abortus virulent strain 2308 and
attenuated strain RB51 were from our culture collection. E. coli strain DH5
(GibcoBRL, Gaithersburg, Md.) was used for
producing the necessary plasmid constructs. Brucellae were grown either
in Trypticase soy broth (TSB) or on Trypticase soy agar (TSA) plates.
All experiments with live brucellae were performed in a biosafety level
3 facility.
Construction of recombinant strain RB51 overexpressing Cu/Zn
SOD.
Recombinant plasmid pBAII-3, containing the gene for B. abortus Cu/Zn SOD (sodC) along with its own promoter,
was initially obtained from a pUC9 genomic library of B. abortus strain 2308 (10). A 1.1-kb fragment containing
the sodC gene and its promoter sequences was excised from
the insert of pBAII-3 with ClaI restriction enzyme digestion
and subcloned into pBBR1MCS, a broad-host-range plasmid (8);
the resulting plasmid was designated pBBSOD. Initially, E. coli DH5
was transformed with pBBSOD. A colony of E. coli containing pBBSOD was selected on a TSA plate containing
chloramphenicol at a concentration of 30 µg/ml. After confirming the
expression of Cu/Zn SOD by Western blot analysis, we isolated pBBSOD
from E. coli. One microgram of pBBSOD or pBBR1MCS was
electroporated into B. abortus strain RB51 as described
elsewhere (12). Several colonies of strain RB51 containing
the plasmid were obtained from a TSA plate containing chloramphenicol
(30 µg/ml). Strain RB51 containing plasmid pBBSOD and RB51 containing
pBBR1MCS were designated RB51SOD and RB51pBB, respectively.
Overexpression of Cu/Zn SOD by the recombinant strain RB51 containing
the plasmid pBBSOD was examined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analyses.
Purification of Cu/Zn SOD.
Expression of Brucella
Cu/Zn SOD by E. coli DH5
(pBS/SOD) has been previously
described (13). A previously described method was used to
extract Cu/Zn SOD from the E. coli cells using 10 mM
phosphate buffer (pH 7.6) containing 0.1% Triton X-100 (4). The Cu/Zn SOD was purified by applying the extracts on an equilibrated anion-exchange column (HiTrapQ; Pharmacia Biotech). All of the proteins
except Cu/Zn SOD bound to the resin. Cu/Zn SOD present in the
flowthrough was collected, absorbed with polymyxin B beads (Affi-Prep
polymyxin support; Bio-Rad Laboratories, Hercules, Calif.) to remove
the lipopolysaccharide, and dialyzed extensively against
phosphate-buffered saline (PBS). After determining the protein
concentration by the Bradford method (3), aliquots of the
purified Cu/Zn SOD were stored at
70°C until use for enzyme-linked immunosorbent assay (ELISA) or for in vitro stimulation of splenocytes.
SDS-PAGE.
SDS-PAGE was performed using 15% acrylamide gels
according to standard procedures (9). The B. abortus samples for SDS-PAGE were prepared as follows. B. abortus grown on either TSA or TSB was harvested and killed by
incubating for 20 min in a 68°C water bath. The killed bacterial
cells were washed twice with 10 mM Tris-HCl buffer (pH 8.0), and their
cell concentration was adjusted to 10% transmittance at 525 nm.
One-milliliter aliquots of such bacterial suspensions were centrifuged,
resuspended in 100 µl of 10 mM Tris-HCl buffer, and stored at
20°C. Before use, aliquots were mixed with 100 µl of 2× Laemmli
sample buffer (Sigma Chemical Co., St. Louis, Mo.), boiled for 5 min,
and used for SDS-PAGE. Gels containing the separated proteins were
either stained with Coomassie brilliant blue G (Sigma) or used for
Western blot analysis.
Western blotting.
Western blotting was performed as
previously described (28). Briefly, proteins separated by
SDS-PAGE were transferred to a nitrocellulose membrane by using a
Trans-blot semidry system (Bio-Rad Laboratories, Hercules, Calif.). The
membranes were blocked with 2% bovine serum albumin solution and used
for reaction with either goat 48 serum (from a goat hyperimmunized with
strain RB51 [18]) or goat anti-B. abortus
Cu/Zn SOD sera (13). The membranes were developed with
appropriate secondary antibody conjugated with horseradish peroxidase
(ICN Biochemicals, Inc., Aurora, Ohio).
Mice protection and clearance experiments.
Three- to
four-week-old female BALB/c mice were purchased from Charles River
Laboratories, Wilmington, Mass.). Mice were given 1 week of rest before
the experiments were started. Ten mice of each group were each
vaccinated with ~4 × 108 CFU of RB51SOD, RB51pBB,
or RB51. As a negative control, another group of 10 mice was injected
with saline alone. Three mice from each group were bled at 3 and 6 weeks postinoculation (p.i.) to obtain sera for ELISA and Western blot
analyses. Also at 6 weeks p.i., three mice from each group were
sacrificed and their splenocytes were used for in vitro culturing to
determine cytokine production. At 7 weeks p.i., seven mice from each
group were challenge infected intraperitoneally with 2 × 104 CFU of B. abortus strain 2308 i.p. Two
weeks after the challenge infection, the mice were killed, bacteria
from their spleens were recovered, and numbers of CFU were determined.
The protection part of the experiment was repeated two more times with
five mice per group; in these experiments, only strains RB51SOD and
RB51 were used as vaccines.
In a separate experiment, groups of 15 mice each were inoculated
intraperitoneally with ~6 × 108 CFU of strains
RB51SOD and RB51. Five mice from each group were sacrificed at 1, 3, and 6 weeks p.i., and the bacterial numbers in their spleens were determined.
ELISA.
In the inoculated mice, the presence of serum IgG,
IgG1, and IgG2a isotypes with specificity to the Cu/Zn SOD were
determined by indirect ELISA. The purified recombinant Cu/Zn SOD was
diluted to 5 µg/ml in carbonate buffer (pH 9.6) and used to coat the
wells of polystyrene plates (100 µl/well; Nunc-Immuno plate with
MaxiSorp surface). After overnight incubation at 4°C, the plates were
washed four times in wash buffer (Tris-buffered saline [pH 7.4] with 0.05% Tween 20) and blocked with 2% bovine serum albumin in
Tris-buffered saline. After 1 h at room temperature, the blocking
solution was discarded, and the serum samples (1:100 dilution in
blocking solution) were added to the wells (50 µl/well). Each serum
sample was tested in triplicate wells. The plates were incubated for
4 h at room temperature and washed four times, and
isotype-specific goat anti-mouse horseradish peroxidase conjugates
(Caltag Laboratories, San Francisco, Calif.) were added (50 µl/well)
at an appropriate dilution. After 1 h of incubation at room
temperature, the plates were washed four times, and 100 µl of
substrate solution (TMB Microwell peroxidase substrate; Kirkegaard & Perry Laboratories, Gaithersburg, Md.) was added to each well. After 20 min of incubation at room temperature, the enzyme reaction was stopped
by adding 100 µl of stop solution (0.185 M sulfuric acid), and the
absorbance at 450 nm was recorded with a microplate reader (Molecular
Devices, Sunnyvale, Calif.).
Cytokine quantitation.
Splenocytes from the inoculated mice
were obtained as previously described (28) and cultured in
the presence of 0.5 to 2.0 µg of Cu/Zn SOD, 10 µg of B. abortus RB51 crude extract (28), 0.5 µg of
concanavalin A, or no additives (unstimulated control). The cells were
cultured for 5 days, and their supernatants were tested for the
presence of gamma interferon (IFN-
) and interleukin-4 (IL-4) by
previously described sandwich ELISAs (28) using recombinant mouse IFN-
or IL-4 (PharMingen, San Diego, Calif.) as standards. In
these assays, the lower detection limits were 100 and 10 pg for the
IFN-
and IL-4 assays, respectively. The assays were performed in triplicate.
Statistical analyses.
The counts of bacterial CFU in the
spleens of mice were analyzed by Student's t test. IFN-
production data were subjected to analysis of variance, and the means
were compared using Tukey's honestly significant difference procedure
(11).
 |
RESULTS |
Overexpression of self antigen.
As shown in Fig.
1, B. abortus strain RB51SOD
overexpressed the Cu/Zn SOD protein. Densitometric analysis of the
Coomassie blue-stained gel (Fig. 1A) indicated that the expression of
Cu/Zn SOD protein in strain RB51SOD was approximately 10 times that of
strain RB51 or strain RB51pBB (data not shown). Western blotting with
antisera specific to Cu/Zn SOD revealed an additional reactive band of
~40 kDa (Fig. 1B). This band most probably is the dimer of Cu/Zn SOD;
the presence of such a dimer that is resistant to SDS treatment has
been reported for the purified Cu/Zn SOD of B. abortus
(4). In addition to Cu/Zn SOD, a protein of ~27 kDa was
expressed in significant amounts by strains RB51pBB and RB51SOD (Fig.
1A). Most likely, this protein was chloramphenicol acetyltransferase
(26,966 Da in size, based on the deduced amino acid sequence) that was
encoded by the antibiotic resistance gene present on plasmid pBBR1MCS
(8).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
Demonstration of overexpression of Cu/Zn SOD in strain
RB51SOD by SDS-PAGE (A) and Western blot analysis (B). (A) Lane 1, molecular weight marker; lanes 2 to 4, contain antigens of strains
RB51, RB51pBB, and RB51SOD, respectively. The gel was stained with
Coomassie brilliant blue G. (B) Lanes 1 and 2, the antigens of strains
RB51pBB and RB51SOD, respectively. The sera indicated below each blot
were used as the primary antibodies for reacting with the antigens.
Asterisks indicate the Cu/Zn SOD protein; numbers at the left indicate
approximate molecular masses in kilodaltons.
|
|
Enhancement in protection conferred by strain RB51SOD.
Mice
vaccinated with strain RB51SOD had significantly lower bacterial
numbers in their spleens compared to those vaccinated with strain RB51
or RB51pBB, indicating enhanced protection against challenge
(P
0.01 in experiments 1 and 2; P
0.05 in experiment 3) (Fig. 2). There was no significant
difference in the level of protection between mice vaccinated with
strain RB51 and those vaccinated with strain RB51pBB. Mice in these two
groups were significantly protected compared to the
saline-vaccinated control group (P
0.001) (Fig.
2).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
Resistance to B. abortus 2308 challenge
infection in mice vaccinated with strains RB51SOD, RB51pBB, and RB51.
Two weeks after challenge infection, the number of strain 2308 CFU in
the spleen was determined. The mean value in each group is indicated by
a solid horizontal line. The horizontal broken line above the
x axis indicates the lower detection limit (<20
CFU/spleen). The P value indicated in the RB51SOD group is
in comparison with the RB51 group. In all three experiments, strain
RB51-vaccinated mice contained significantly lower numbers of CFUs in
comparison with the saline-inoculated group (P 0.001). In experiment 1, there was no significant difference in
the number of CFU between RB51- and RB51pBB-vaccinated groups
(P > 0.05).
|
|
To determine if the enhanced protective response could be due to
increased survivability of strain RB51SOD in mice, we determined
the
number of bacteria colonizing the spleens of vaccinated mice
over time.
At 1, 3, and 6 weeks p.i., no significant difference
was observed in
the number of bacteria in the spleen of mice inoculated
with either
strain RB51 or strain RB51SOD, indicating similar
attenuation levels.
At 1 and 3 weeks p.i., the RB51SOD-inoculated
mice had (4.2 ± 0.65) × 10
5, and (3.7 ± 0.55) × 10
3 CFU/spleen, respectively, while the RB51-inoculated
mice had
(5 ± 0.3) × 10
5 and (2.82 ± 0.43) × 10
3 CFU/spleen, respectively. At 6 weeks
p.i., three mice in both
groups contained no detectable number of
bacteria (lower detection
limit was 20 CFU/spleen); only 80 and 40 CFU
could be isolated
from the other two mice of the RB51SOD and RB51
groups,
respectively.
Immune responses of mice vaccinated with strain RB51SOD.
Sera
from mice vaccinated with strain RB51SOD, but not those vaccinated with
strain RB51 or RB51pBB, contained antibodies to Cu/Zn SOD protein. In
ELISA to detect SOD-specific IgG, the absorbance readings of mouse sera
collected 3 and 4 weeks after vaccination with RB51SOD were 1.104 ± 0.21 and 1.906 ± 0.16, respectively. Subisotype analysis of
these antibodies indicated that they were predominantly of IgG2a
(absorbance readings of 0.728 ± 0.18 and 1.682 ± 0.2 for
the 3- and 6-week sera, respectively). In both IgG- and IgG2a-specific
ELISAs, the absorbance values with sera from other groups of mice were
not different from the blank values (<0.01). No IgG1 antibodies
specific to the Cu/Zn SOD were detected in sera of any group of mice
(data not shown). Also, splenocytes from strain RB51SOD-vaccinated mice
secreted IFN-
upon in vitro stimulation with the recombinant Cu/Zn
SOD (Table 1). Splenocytes from all of
the vaccinated mice produced similar levels of IFN-
when stimulated
with B. abortus RB51 antigen extract (Table 1). However, no
IL-4 was detected in any of the culture supernatants of splenocytes
stimulated with the specific antigens (data not shown). Splenocytes
from all groups of mice, including the saline-inoculated group,
produced similar levels of IL-4 and IFN-
upon stimulation with
concanavalin A (data not shown).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Concentration of IFN- in culture supernatants of
splenocytes upon in vitro stimulation with recombinant Cu/Zn SOD or
RB51 antigen extract for 5 days
|
|
 |
DISCUSSION |
Overexpression of self proteins has been performed in
several bacterial systems to complement the deleted or lost gene
expression (14), to study the functional aspects of the gene
product (15, 17, 21, 31), or to obtain increased amounts of
a protein in its native state (19). However, to the best of
our knowledge, this strategy has heretofore not been used to enhance
the protective capabilities of live vaccines. The studies presented
here clearly indicate that such a strategy indeed results in enhanced protection.
There is sufficient evidence that the complete protein or certain
epitopes of Brucella Cu/Zn SOD can induce protective
immunity in mice (13, 25). However, the contribution of
B. abortus Cu/Zn SOD protein to the protective immunity
conferred by a live vaccine strain is not known. The absence of
detectable antibody and selected CMI responses against Cu/Zn SOD in
mice vaccinated with strain RB51 suggest that there is no significant
role for this protein in the protection conferred by this attenuated
vaccine strain. As demonstrated in this study, mice vaccinated with
RB51SOD, but not RB51, developed Cu/Zn SOD-specific immune responses.
This suggests that a quantity of Cu/Zn SOD that is higher than that produced by strain RB51 is required to induce an immune response in
mice. The amount of Cu/Zn SOD produced by strain RB51 from the
chromosomal gene, which is detectable by Western blotting (Fig. 1B),
may not be sufficient to induce an immune response. Also, Rafie-Kolpin
et al. (16) reported that the expression of Cu/Zn SOD in
B. abortus virulent strain 2308 is decreased during intracellular growth in bovine macrophages. Studies in our laboratory indicate that the activity of the sodC gene promoter in
strain RB51 is decreased upon intracellular localization in J774A.1
cells, a murine macrophage-like cell line (29). Taken
together, the available data indicate that the decreased expression is
a probable reason for the lack of an immune response against
Brucella Cu/Zn SOD in strain RB51-vaccinated animals.
Mice vaccinated with strain RB51SOD developed a Th1-type of immune
response to the Cu/Zn SOD, as indicated by the specific induction of
serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-
,
but not IL-4, by the Cu/Zn SOD-stimulated splenocytes (24).
The enhanced protective immunity conferred by strain RB51SOD could be
attributed to the specific cell-mediated responses, especially IFN-
secretion (32). It is also possible that the overexpression
of Cu/Zn SOD in strain RB51 alters the processing and presentation of
other protective antigens by a yet unidentified mechanism and that the
observed immune response to Cu/Zn SOD does not play a crucial role in
the enhanced protection. Further studies aimed at unraveling the basis
for the observed enhanced protection are under way in our laboratory.
Such studies may also provide clues as to the reasons for the observed
highly variable degree of protection afforded by strain RB51SOD,
especially in experiments 1 and 2 (Fig. 2). Although the matter is
still controversial (10, 22, 26), the Cu/Zn SOD is
considered a virulence factor of B. abortus by some
researchers (26). Overexpression of a virulence factor may
enhance the persistence or virulence characteristic of an attenuated
pathogen. However, this appears not to be the case in our study, since
the patterns of clearance or persistence of strains RB51 and RB51SOD in
the vaccinated mice were similar (Fig. 3). It remains to be tested if
the induction of a measurable immune response to Cu/Zn SOD and the
enhanced protective response seen in RB51SOD-vaccinated mice can also
be achieved in other animal species such as cattle. Cattle vaccinated with strain RB51 also do not develop antibodies or a lymphocyte proliferation response to Cu/Zn SOD (23). If cattle were to respond to strain RB51SOD immunization as did mice, in addition to
increasing the efficacy of the vaccine, it could also be the basis for
development of a serological assay for the detection of strain
RB51SOD-vaccinated animals.
Overexpression of a nonprotective 18-kDa outer membrane lipoprotein of
B. abortus (27) in strain RB51 did not enhance
its protective ability although it increased IFN-
production
(unpublished data). This indicates that selection of an appropriate
protein for the overexpression is important to achieve the enhanced
protectivity of the vaccine. It is our opinion that overexpression of
some other Brucella protective antigen(s) in strain RB51
could also result in enhanced protective capabilities. Moreover, this
strategy can also be used for other live bacterial vaccines as long as the overexpressed antigen does not affect the attenuation
characteristic of the vaccine strain. Because of the enhanced vaccine
efficacy, lower doses of the vaccine may be used to obtain the same
level of protection as provided by the original vaccine.
 |
ACKNOWLEDGMENT |
This work was supported by U.S. Department of Agriculture
grant 97-35204-4483.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Center for
Molecular Medicine and Infectious Diseases, 1410 Prices Fork Rd.,
Blacksburg, VA 24061. Phone: (540) 231-7757. Fax: (540) 231-3426. E-mail: rvemulap{at}vt.edu.
Editor:
D. L. Burns
 |
REFERENCES |
| 1.
|
Acha, P., and B. Szyfres.
1980.
Zoonoses and communicable diseases common to man and animals, p. 28-45.
Pan American Health Organization, Washington, D.C.
|
| 2.
|
Araya, L. N., and A. J. Winter.
1990.
Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum.
Infect. Immun.
58:254-256[Abstract/Free Full Text].
|
| 3.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 4.
|
Bricker, B. J.,
L. B. Tabatabai,
B. A. Judge,
B. L. Deyoe, and J. E. Mayfield.
1990.
Cloning, expression, and occurrence of the Brucella Cu-Zn superoxide dismutase.
Infect. Immun.
58:2935-2939[Abstract/Free Full Text].
|
| 5.
|
Corbel, M. J.
1997.
Brucellosis: an overview.
Emerg. Infect. Dis.
3:213-221[Medline].
|
| 6.
|
Jimenez de Bagues, M. P.,
P. H. Elzer,
S. M. Jones,
J. M. Blasco,
F. M. Enright,
G. G. Schurig, and A. J. Winter.
1994.
Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.
Infect. Immun.
62:4990-4996[Abstract/Free Full Text].
|
| 7.
|
Kerksiek, K. M., and E. G. Pamer.
1999.
T cell responses to bacterial infection.
Curr. Opin. Immunol.
11:400-405[CrossRef][Medline].
|
| 8.
|
Kovach, M. E.,
R. W. Phillips,
P. H. Elzer,
R. M. Roop II, and K. M. Peterson.
1994.
pBBR1MCS: a broad-host-range cloning vector.
BioTechniques
16:800-802[Medline].
|
| 9.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 10.
|
Latimer, E.,
J. Simmers,
N. Sriranganathan,
R. M. Roop,
G. G. Schurig, and S. M. Boyle.
1992.
Brucella abortus deficient in copper/zinc superoxide dismutase is virulent in BALB/c mice.
Microb. Pathog.
12:105-113[CrossRef][Medline].
|
| 11.
|
Littell, R. C.,
G. A. Milliken,
W. W. Stroup, and R. D. Wolfinger.
1996.
SAS® system for mixed models.
SAS Institute Inc., Cary, N.C.
|
| 12.
|
McQuiston, J. R.,
G. G. Schurig,
N. Sriranganathan, and S. M. Boyle.
1995.
Transformation of Brucella species with suicide and broad host-range plasmids.
Methods Mol. Biol.
47:143-148[Medline].
|
| 13.
|
Oñate, A. A.,
R. Vemulapalli,
E. Andrews,
G. G. Schurig,
S. M. Boyle, and H. Folch.
1999.
Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus.
Infect. Immun.
67:986-988[Abstract/Free Full Text].
|
| 14.
|
Papavinasasundaram, K. G.,
M. J. Colston, and E. O. Davis.
1998.
Construction and complementation of a recA deletion mutant of Mycobacterium smegmatis reveals that the intein in Mycobacterium tuberculosis recA does not affect RecA function.
Mol. Microbiol.
30:525-534[CrossRef][Medline].
|
| 15.
|
Payton, M.,
R. Auty,
R. Delgoda,
M. Everett, and E. Sim.
1999.
Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance.
J. Bacteriol.
181:1343-1347[Abstract/Free Full Text].
|
| 16.
|
Rafie-Kolpin, M.,
R. C. Essenberg, and J. H. Wyckoff.
1996.
Identification and comparison of macrophage-induced proteins and proteins induced under various stress conditions in Brucella abortus.
Infect. Immun.
64:5274-5283[Abstract].
|
| 17.
|
Rastogi, V.,
M. Labes,
T. Finan, and R. Watson.
1992.
Overexpression of the dctA gene in Rhizobium meliloti: effect on transport of C4 dicarboxylates and symbiotic nitrogen fixation.
Can. J. Microbiol.
38:555-562[Medline].
|
| 18.
|
Roop, R. M., II,
M. L. Price,
B. E. Dunn,
S. M. Boyle,
N. Sriranganathan, and G. G. Schurig.
1992.
Molecular cloning and nucleotide sequence analysis of the gene encoding the immunoreactive Brucella abortus Hsp60 protein, BA60K.
Microb. Pathog.
12:47-62[CrossRef][Medline].
|
| 19.
|
Sanchez, J., and J. Holmgren.
1989.
Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.
Proc. Natl. Acad. Sci. USA
86:481-485[Abstract/Free Full Text].
|
| 20.
|
Schurig, G. G.,
R. M. Roop,
T. Bagchi,
S. Boyle,
D. Buhrman, and N. Sriranganathan.
1991.
Biological properties of RB51: a stable rough strain of Brucella abortus.
Vet. Microbiol.
28:171-188[CrossRef][Medline].
|
| 21.
|
Silva, A.,
R. Fando, and J. A. Benitez.
1998.
Overexpression of a mutant B subunit in toxigenic Vibrio cholerae diminishes production of active cholera toxin in vivo.
Curr. Microbiol.
37:231-235[CrossRef][Medline].
|
| 22.
|
Sriranganathan, N.,
S. M. Boyle,
G. G. Schurig, and H. Misra.
1991.
Superoxide dismutases of virulent and avirulent strains of Brucella abortus.
Vet. Microbiol.
26:359-366[CrossRef][Medline].
|
| 23.
|
Stevens, M. G.,
L. B. Tabatabai,
S. C. Olsen, and N. F. Cheville.
1994.
Immune responses to superoxide dismutase and synthetic peptides of superoxide dismutase in cattle vaccinated with Brucella abortus strain 19 or RB51.
Vet. Microbiol.
41:383-389[CrossRef][Medline].
|
| 24.
|
Stevens, T. L.,
A. Bossie,
V. M. Sanders,
R. Fernandez-Botran,
R. L. Coffman,
T. R. Mosmann, and E. S. Vitetta.
1988.
Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.
Nature
334:255-258[CrossRef][Medline].
|
| 25.
|
Tabatabai, L. B., and G. W. Pugh, Jr.
1994.
Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.
Vaccine
12:919-924[CrossRef][Medline].
|
| 26.
|
Tatum, F. M.,
P. G. Detilleux,
J. M. Sacks, and S. M. Halling.
1992.
Construction of Cu-Zn superoxide dismutase deletion mutants of Brucella abortus: analysis of survival in vitro in epithelial and phagocytic cells and in vivo in mice.
Infect. Immun.
60:2863-2869[Abstract/Free Full Text].
|
| 27.
|
Vemulapalli, R.,
S. Cravero,
C. L. Calvert,
T. E. Toth,
S. M. Boyle,
N. Sriranganathan, and G. G. Schurig.
2000.
Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kDa outer membrane protein of Brucella abortus.
Clin. Diagn. Lab. Immunol.
7:114-118[Abstract/Free Full Text].
|
| 28.
|
Vemulapalli, R.,
A. J. Duncan,
S. M. Boyle,
N. Sriranganathan,
T. E. Toth, and G. G. Schurig.
1998.
Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51.
Infect. Immun.
66:5684-5691[Abstract/Free Full Text].
|
| 29.
|
Vemulapalli, R.,
Y. He,
S. M. Boyle,
N. Sriranganathan, and G. G. Schurig.
2000.
Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses.
Infect. Immun.
68:3290-3296[Abstract/Free Full Text].
|
| 30.
|
Winter, A. J.,
G. G. Schurig,
S. M. Boyle,
N. Sriranganathan,
J. S. Bevins,
F. M. Enright,
P. H. Elzer, and J. D. Kope.
1996.
Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Am. J. Vet. Res.
57:677-683[Medline].
|
| 31.
|
Wright, R.,
C. Stephens, and L. Shapiro.
1997.
The CcrM DNA methyltransferase is widespread in the alpha subdivision of proteobacteria, and its essential functions are conserved in Rhizobium meliloti and Caulobacter crescentus.
J. Bacteriol.
179:5869-5877[Abstract/Free Full Text].
|
| 32.
|
Zhan, Y., and C. Cheers.
1993.
Endogenous gamma interferon mediates resistance to Brucella abortus infection.
Infect. Immun.
61:4899-4901[Abstract/Free Full Text].
|
Infection and Immunity, June 2000, p. 3286-3289, Vol. 68, No. 6
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Olsen, S. C., Boyle, S. M., Schurig, G. G., Sriranganathan, N. N.
(2009). Immune Responses and Protection against Experimental Challenge after Vaccination of Bison with Brucella abortus Strain RB51 or RB51 Overexpressing Superoxide Dismutase and Glycosyltransferase Genes. CVI
16: 535-540
[Abstract]
[Full Text]
-
Bhattacharjee, A. K., Izadjoo, M. J., Zollinger, W. D., Nikolich, M. P., Hoover, D. L.
(2006). Comparison of Protective Efficacy of Subcutaneous versus Intranasal Immunization of Mice with a Brucella melitensis Lipopolysaccharide Subunit Vaccine.. Infect. Immun.
74: 5820-5825
[Abstract]
[Full Text]
-
Luo, D., Ni, B., Li, P., Shi, W., Zhang, S., Han, Y., Mao, L., He, Y., Wu, Y., Wang, X.
(2006). Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice.. Infect. Immun.
74: 2734-2741
[Abstract]
[Full Text]
-
Vemulapalli, T. H., Vemulapalli, R., Schurig, G. G., Boyle, S. M., Sriranganathan, N.
(2006). Role in Virulence of a Brucella abortus Protein Exhibiting Lectin-Like Activity. Infect. Immun.
74: 183-191
[Abstract]
[Full Text]
-
Sanakkayala, N., Sokolovska, A., Gulani, J., HogenEsch, H., Sriranganathan, N., Boyle, S. M., Schurig, G. G., Vemulapalli, R.
(2005). Induction of Antigen-Specific Th1-Type Immune Responses by Gamma-Irradiated Recombinant Brucella abortus RB51. CVI
12: 1429-1436
[Abstract]
[Full Text]
-
Izadjoo, M. J., Bhattacharjee, A. K., Paranavitana, C. M., Hadfield, T. L., Hoover, D. L.
(2004). Oral Vaccination with Brucella melitensis WR201 Protects Mice against Intranasal Challenge with Virulent Brucella melitensis 16M. Infect. Immun.
72: 4031-4039
[Abstract]
[Full Text]
-
Munoz-Montesino, C., Andrews, E., Rivers, R., Gonzalez-Smith, A., Moraga-Cid, G., Folch, H., Cespedes, S., Onate, A. A.
(2004). Intraspleen Delivery of a DNA Vaccine Coding for Superoxide Dismutase (SOD) of Brucella abortus Induces SOD-Specific CD4+ and CD8+ T Cells. Infect. Immun.
72: 2081-2087
[Abstract]
[Full Text]
-
Onate, A. A., Cespedes, S., Cabrera, A., Rivers, R., Gonzalez, A., Munoz, C., Folch, H., Andrews, E.
(2003). A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice. Infect. Immun.
71: 4857-4861
[Abstract]
[Full Text]
-
He, Y., Vemulapalli, R., Schurig, G. G.
(2002). Recombinant Ochrobactrum anthropi Expressing Brucella abortus Cu,Zn Superoxide Dismutase Protects Mice against B. abortus Infection Only after Switching of Immune Responses to Th1 Type. Infect. Immun.
70: 2535-2543
[Abstract]
[Full Text]
-
Ribeiro, L. A., Azevedo, V., Le Loir, Y., Oliveira, S. C., Dieye, Y., Piard, J.-C., Gruss, A., Langella, P.
(2002). Production and Targeting of the Brucella abortus Antigen L7/L12 in Lactococcus lactis: a First Step towards Food-Grade Live Vaccines against Brucellosis. Appl. Environ. Microbiol.
68: 910-916
[Abstract]
[Full Text]
-
He, Y., Vemulapalli, R., Zeytun, A., Schurig, G. G.
(2001). Induction of Specific Cytotoxic Lymphocytes in Mice Vaccinated with Brucella abortus RB51. Infect. Immun.
69: 5502-5508
[Abstract]
[Full Text]
-
Al-Mariri, A., Tibor, A., Mertens, P., De Bolle, X., Michel, P., Godefroid, J., Walravens, K., Letesson, J.-J.
(2001). Protection of BALB/c Mice against Brucella abortus 544 Challenge by Vaccination with Bacterioferritin or P39 Recombinant Proteins with CpG Oligodeoxynucleotides as Adjuvant. Infect. Immun.
69: 4816-4822
[Abstract]
[Full Text]
-
Vemulapalli, R., He, Y., Boyle, S. M., Sriranganathan, N., Schurig, G. G.
(2000). Brucella abortus Strain RB51 as a Vector for Heterologous Protein Expression and Induction of Specific Th1 Type Immune Responses. Infect. Immun.
68: 3290-3296
[Abstract]
[Full Text]